MA46649A - Méthodes et compositions d'immunothérapie impliquant des modulateurs de la voie métabolique du tryptophane - Google Patents

Méthodes et compositions d'immunothérapie impliquant des modulateurs de la voie métabolique du tryptophane

Info

Publication number
MA46649A
MA46649A MA046649A MA46649A MA46649A MA 46649 A MA46649 A MA 46649A MA 046649 A MA046649 A MA 046649A MA 46649 A MA46649 A MA 46649A MA 46649 A MA46649 A MA 46649A
Authority
MA
Morocco
Prior art keywords
modulators
compositions
methods
metabolic pathway
tryptophan metabolic
Prior art date
Application number
MA046649A
Other languages
English (en)
Inventor
Hyam I Levitsky
Evan Paul Thomas
Juno Therapeutics Inc C/O
Original Assignee
Juno Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Juno Therapeutics Inc filed Critical Juno Therapeutics Inc
Publication of MA46649A publication Critical patent/MA46649A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464411—Immunoglobulin superfamily
    • A61K39/464412—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y113/00—Oxidoreductases acting on single donors with incorporation of molecular oxygen (oxygenases) (1.13)
    • C12Y113/11—Oxidoreductases acting on single donors with incorporation of molecular oxygen (oxygenases) (1.13) with incorporation of two atoms of oxygen (1.13.11)
    • C12Y113/11011—Tryptophan 2,3-dioxygenase (1.13.11.11), i.e. indolamine 2,3-dioxygenase 2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y113/00—Oxidoreductases acting on single donors with incorporation of molecular oxygen (oxygenases) (1.13)
    • C12Y113/11—Oxidoreductases acting on single donors with incorporation of molecular oxygen (oxygenases) (1.13) with incorporation of two atoms of oxygen (1.13.11)
    • C12Y113/11052—Indoleamine 2,3-dioxygenase (1.13.11.52), i.e. indoleamine 2,3-dioxygenase 1
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/11—Protein-serine/threonine kinases (2.7.11)
    • C12Y207/11001—Non-specific serine/threonine protein kinase (2.7.11.1), i.e. casein kinase or checkpoint kinase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/11—Protein-serine/threonine kinases (2.7.11)
    • C12Y207/11013—Protein kinase C (2.7.11.13)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/30—Coculture with; Conditioned medium produced by tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/555—Interferons [IFN]
    • G01N2333/57—IFN-gamma

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
MA046649A 2016-10-13 2017-10-13 Méthodes et compositions d'immunothérapie impliquant des modulateurs de la voie métabolique du tryptophane MA46649A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662407776P 2016-10-13 2016-10-13
US201762514767P 2017-06-02 2017-06-02

Publications (1)

Publication Number Publication Date
MA46649A true MA46649A (fr) 2019-08-21

Family

ID=60421838

Family Applications (2)

Application Number Title Priority Date Filing Date
MA046649A MA46649A (fr) 2016-10-13 2017-10-13 Méthodes et compositions d'immunothérapie impliquant des modulateurs de la voie métabolique du tryptophane
MA050839A MA50839A (fr) 2016-10-13 2017-10-13 Méthodes et compositions d'immunothérapie impliquant des modulateurs de la voie métabolique du tryptophane

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA050839A MA50839A (fr) 2016-10-13 2017-10-13 Méthodes et compositions d'immunothérapie impliquant des modulateurs de la voie métabolique du tryptophane

Country Status (15)

Country Link
US (1) US11896615B2 (fr)
EP (2) EP4190335A1 (fr)
JP (2) JP2019533676A (fr)
KR (1) KR20190084053A (fr)
CN (1) CN110381963A (fr)
AU (1) AU2017343780B2 (fr)
BR (1) BR112019006652A2 (fr)
CA (1) CA3037387A1 (fr)
ES (1) ES2939646T3 (fr)
IL (1) IL265848A (fr)
MA (2) MA46649A (fr)
MX (1) MX2019004181A (fr)
PH (1) PH12019500803A1 (fr)
SG (1) SG11201903282TA (fr)
WO (1) WO2018071873A2 (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA40253A (fr) 2014-07-15 2017-05-24 Juno Therapeutics Inc Cellules modifiées pour thérapie cellulaire adoptive
MA42895A (fr) 2015-07-15 2018-05-23 Juno Therapeutics Inc Cellules modifiées pour thérapie cellulaire adoptive
EP4218751A3 (fr) 2016-02-23 2024-03-06 Cancer Research Technology Ltd Produit alimentaire dépourvu d'au moins deux acides aminés non essentiels
GB201701332D0 (en) * 2017-01-26 2017-03-15 Tc Biopharm Ltd Immune cells with modified metabolism and their use thereof
PT3618842T (pt) * 2017-05-01 2024-01-12 Juno Therapeutics Inc Combinação de uma terapia celular e de um composto imunomodulador
MA50860A (fr) 2017-11-01 2020-09-09 Juno Therapeutics Inc Récepterus chimériques d'antigène contre l'antigène de maturation des cellules b et polynucleotides codants
WO2019089982A1 (fr) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Procédé d'évaluation de l'activité de récepteurs antigéniques de recombinaison
EP3740495A1 (fr) * 2018-01-15 2020-11-25 Universität Heidelberg Polynucléotides se liant à nfat
EP3765094A4 (fr) 2018-03-15 2021-12-22 KSQ Therapeutics, Inc. Compositions de régulation génique et procédés pour améliorer l'immunothérapie
US20210181179A1 (en) * 2018-05-25 2021-06-17 Memorial Sloan Kettering Cancer Center Diagnosis and treatment of immunotherapy-induced neurotoxicity
WO2019231805A1 (fr) * 2018-05-30 2019-12-05 The Johns Hopkins University CELLULES MYÉLOÏDES IMMATURES DÉFICIENTES EN NF-κB P50 ET LEUR UTILISATION DANS LE TRAITEMENT DU CANCER
CN111035623B (zh) * 2018-10-12 2021-11-23 国家纳米科学中心 一种ido1多肽纳米抑制剂及其制备方法和应用
CN110592014A (zh) * 2019-08-14 2019-12-20 广东美赛尔细胞生物科技有限公司 一种在nk细胞治疗中免辐照体外体内持续去除饲养细胞的方法
KR20210030883A (ko) * 2019-09-10 2021-03-18 고려대학교 세종산학협력단 인돌아민 2,3-이산소화 효소를 포함하는 전립선암 진단용 마커
JP2022554348A (ja) 2019-11-05 2022-12-28 ジュノー セラピューティクス インコーポレイテッド 治療用ｔ細胞組成物の属性を決定する方法
US20230218669A1 (en) * 2020-03-31 2023-07-13 Fred Hutchinson Cancer Center Augmenting antigen-negative cell death in antigen-targeted immunotherapies
WO2021222451A2 (fr) * 2020-04-28 2021-11-04 City Of Hope Technologie d'édition de gène marqué pour le tri et l'enrichissement de cellules cliniques
US20230348585A1 (en) * 2020-05-05 2023-11-02 St. Jude Children's Research Hospital, Inc. Methods for treating or reducing the severity of a viral infection
JP2023528215A (ja) 2020-05-13 2023-07-04 ジュノー セラピューティクス インコーポレイテッド 臨床応答に関連する特徴量の特定方法およびその使用
US20220010028A1 (en) * 2020-07-09 2022-01-13 The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center Compositions and methods for treating fibroids
US20220064596A1 (en) * 2020-08-25 2022-03-03 Kite Pharma, Inc. T cells with improved functionality
CN114306601A (zh) * 2020-09-28 2022-04-12 中国科学院上海营养与健康研究所 一种l型氨基酸转运蛋白抑制剂或拮抗剂有效干预糖尿病的方法
GB202018554D0 (en) * 2020-11-25 2021-01-06 Cancer Research Tech Ltd Nucleic acid constructs and cells
WO2022236099A1 (fr) * 2021-05-06 2022-11-10 Mayo Foundation For Medical Education And Research Évaluation et traitement du cancer
WO2023080788A1 (fr) * 2021-11-05 2023-05-11 Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Déplétion de tryptophane induisant la production et la présentation de tryptophane à des substitutions de phénylalanine
WO2023166492A2 (fr) * 2022-03-04 2023-09-07 Antido Therapeutics International Sàrl Inhibiteurs doubles de tryptophane dioxygénases (ido1 et tdo) et leur utilisation en thérapie
CN114657158B (zh) * 2022-05-25 2022-10-21 深圳吉诺因生物科技有限公司 Ido1相关疫苗及其应用
WO2023230548A1 (fr) 2022-05-25 2023-11-30 Celgene Corporation Procédé de prédiction d'une réponse à une thérapie par lymphocyte t
CN114878723B (zh) * 2022-07-04 2022-09-23 中日友好医院(中日友好临床医学研究所) 快速诊断多发性骨髓瘤的代谢标志物及应用
CN116251088A (zh) * 2022-12-19 2023-06-13 浙江大学医学院附属第一医院 3-羟基邻氨基苯甲酸在抑制肝癌生长中的应用

Family Cites Families (154)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4452773A (en) 1982-04-05 1984-06-05 Canadian Patents And Development Limited Magnetic iron-dextran microspheres
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5049386A (en) 1985-01-07 1991-09-17 Syntex (U.S.A.) Inc. N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4946787A (en) 1985-01-07 1990-08-07 Syntex (U.S.A.) Inc. N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US4795698A (en) 1985-10-04 1989-01-03 Immunicon Corporation Magnetic-polymer particles
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
WO1990007380A2 (fr) 1988-12-28 1990-07-12 Stefan Miltenyi Procedes et matieres pour la separation magnetique a gradient eleve de matieres biologiques
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
WO1991017424A1 (fr) 1990-05-03 1991-11-14 Vical, Inc. Acheminement intracellulaire de substances biologiquement actives effectue a l'aide de complexes de lipides s'auto-assemblant
US5200084A (en) 1990-09-26 1993-04-06 Immunicon Corporation Apparatus and methods for magnetic separation
JP3150340B2 (ja) 1990-11-13 2001-03-26 イムネクス コーポレイション 二機能選択可能融合遺伝子
US5356802A (en) 1992-04-03 1994-10-18 The Johns Hopkins University Functional domains in flavobacterium okeanokoites (FokI) restriction endonuclease
US5487994A (en) 1992-04-03 1996-01-30 The Johns Hopkins University Insertion and deletion mutants of FokI restriction endonuclease
US5436150A (en) 1992-04-03 1995-07-25 The Johns Hopkins University Functional domains in flavobacterium okeanokoities (foki) restriction endonuclease
AU6953394A (en) 1993-05-21 1994-12-20 Targeted Genetics Corporation Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
WO1996013593A2 (fr) 1994-10-26 1996-05-09 Procept, Inc. Recepteurs de lymphocites t monocatenaires solubles
WO1996018105A1 (fr) 1994-12-06 1996-06-13 The President And Fellows Of Harvard College Recepteur de lymphocyte t monocatenaire
DE19608753C1 (de) 1996-03-06 1997-06-26 Medigene Gmbh Transduktionssystem und seine Verwendung
US6451995B1 (en) 1996-03-20 2002-09-17 Sloan-Kettering Institute For Cancer Research Single chain FV polynucleotide or peptide constructs of anti-ganglioside GD2 antibodies, cells expressing same and related methods
GB9710807D0 (en) 1997-05-23 1997-07-23 Medical Res Council Nucleic acid binding proteins
GB9710809D0 (en) 1997-05-23 1997-07-23 Medical Res Council Nucleic acid binding proteins
AU742650B2 (en) 1997-10-02 2002-01-10 Altor Bioscience Corporation Soluble single-chain T-cell receptor proteins
DE69900468T2 (de) 1998-05-19 2002-07-18 Avidex Ltd Löslicher t-zell rezeptor
CA2343156A1 (fr) 1998-09-04 2000-03-16 Sloan-Kettering Institute For Cancer Research Recepteurs de fusion specifiques a l'antigene prostatique specifique membranaire et ses utilisations
US6140081A (en) 1998-10-16 2000-10-31 The Scripps Research Institute Zinc finger binding domains for GNN
US6410319B1 (en) 1998-10-20 2002-06-25 City Of Hope CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies
US6534261B1 (en) 1999-01-12 2003-03-18 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US6599692B1 (en) 1999-09-14 2003-07-29 Sangamo Bioscience, Inc. Functional genomics using zinc finger proteins
US7070934B2 (en) 1999-01-12 2006-07-04 Sangamo Biosciences, Inc. Ligand-controlled regulation of endogenous gene expression
US6453242B1 (en) 1999-01-12 2002-09-17 Sangamo Biosciences, Inc. Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites
US7030215B2 (en) 1999-03-24 2006-04-18 Sangamo Biosciences, Inc. Position dependent recognition of GNN nucleotide triplets by zinc fingers
US6794136B1 (en) 2000-11-20 2004-09-21 Sangamo Biosciences, Inc. Iterative optimization in the design of binding proteins
IL150069A0 (en) 1999-12-06 2002-12-01 Sangamo Biosciences Inc Methods of using randomized libraries of zinc finger proteins for the identification of gene function
EP1254369B1 (fr) 2000-02-08 2010-10-06 Sangamo BioSciences, Inc. Cellules destinees a la decouverte de medicaments
WO2001094944A2 (fr) 2000-06-02 2001-12-13 Memorial Sloan-Kettering Cancer Center Cellules presentatrices d'antigene artificiel et leurs methodes d'utilisation
JP2002060786A (ja) 2000-08-23 2002-02-26 Kao Corp 硬質表面用殺菌防汚剤
WO2002077029A2 (fr) 2000-11-07 2002-10-03 City Of Hope Cellules immunitaires specifiques a cd19 redirigees
US7067317B2 (en) 2000-12-07 2006-06-27 Sangamo Biosciences, Inc. Regulation of angiogenesis with zinc finger proteins
US7070995B2 (en) 2001-04-11 2006-07-04 City Of Hope CE7-specific redirected immune cells
US20090257994A1 (en) 2001-04-30 2009-10-15 City Of Hope Chimeric immunoreceptor useful in treating human cancers
MXPA03011082A (es) 2001-06-05 2004-07-08 Lilly Icos Llc Derivados de pirazino-1',2': 1,6-prirido-3,4-b-indol-1,4-diona.
EP1421177A4 (fr) 2001-08-20 2006-06-07 Scripps Research Inst Domaines de fixation en doigt de zinc pour cnn
ES2239246T3 (es) 2001-08-31 2005-09-16 Avidex Limited Receptor soluble de celulas t.
US7939059B2 (en) 2001-12-10 2011-05-10 California Institute Of Technology Method for the generation of antigen-specific lymphocytes
US7262054B2 (en) 2002-01-22 2007-08-28 Sangamo Biosciences, Inc. Zinc finger proteins for DNA binding and gene regulation in plants
US20030170238A1 (en) 2002-03-07 2003-09-11 Gruenberg Micheal L. Re-activated T-cells for adoptive immunotherapy
US20060292618A1 (en) 2002-04-12 2006-12-28 Mellor Andrew L Antigen-presenting cell populations and their use as reagents for enhancing or reducing immune tolerance
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
US7361635B2 (en) 2002-08-29 2008-04-22 Sangamo Biosciences, Inc. Simultaneous modulation of multiple genes
AU2003271904B2 (en) 2002-10-09 2009-03-05 Adaptimmune Limited Single chain recombinant T cell receptors
ATE517992T1 (de) 2002-11-14 2011-08-15 Dharmacon Inc Funktionelle und hyperfunktionelle sirna
US20060275762A1 (en) 2002-11-22 2006-12-07 Bio- Think Tank Co., Ltd., Method of detecting target base sequence of rna interference, method of designing polynucleotide base sequence causing rna interference, method of constructing double-stranded polynucleotide, method of regulating gene expression, base sequence processing apparatus, program for running base sequence processing method on comp
US20050129671A1 (en) 2003-03-11 2005-06-16 City Of Hope Mammalian antigen-presenting T cells and bi-specific T cells
EP2260846B1 (fr) 2003-03-27 2018-11-28 Lankenau Institute for Medical Research Nouveaux procédés pour le traitement du cancer
US20050186289A1 (en) 2003-04-01 2005-08-25 Medical College Of Georgia Research Institute, Inc. Regulation of T cell-mediated immunity by D isomers of inhibitors of indoleamine-2,3-dioxygenase
US7888121B2 (en) 2003-08-08 2011-02-15 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
US8409861B2 (en) 2003-08-08 2013-04-02 Sangamo Biosciences, Inc. Targeted deletion of cellular DNA sequences
US7972854B2 (en) 2004-02-05 2011-07-05 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
CA2561714A1 (fr) 2004-04-08 2005-10-27 Sangamo Biosciences, Inc. Procedes et compositions permettant de traiter les troubles neuropathiques et neurodegeneratifs
AU2005233550B2 (en) 2004-04-08 2010-11-18 Sangamo Therapeutics, Inc. Treatment of neuropathic pain with zinc finger proteins
DE602005022595D1 (de) 2004-06-29 2010-09-09 Immunocore Ltd Einen modifizierten t-zellen-rezeptor exprimierende zellen
EP1773846A4 (fr) 2004-07-13 2008-10-08 Univ British Columbia Inhibiteurs de la indoleamine 2,3-dioxygenase (ido)
WO2007004062A2 (fr) 2005-05-31 2007-01-11 Centre National De La Recherche Scientifique Regulation dependante de la tetracycline de l'arn interferent
EP2196155B1 (fr) 2005-08-10 2015-03-18 C.R.Bard, Inc. Dispositif de biopsie à échantillonnage multiple et introduction unique avec système de transport
US20110305713A1 (en) 2005-10-21 2011-12-15 Medical College Of Georgia Research Institute, Inc Methods and compositions to enhance vaccine efficacy by reprogramming regulatory t cells
US7705022B2 (en) 2005-10-27 2010-04-27 Lankenau Institute For Medical Research IDO inhibitors and methods of use thereof
DK2420494T3 (en) 2006-08-16 2015-01-12 J David Gladstone Inst A Testamentary Trust Established Under The Will Of J David Gladstone Use of thiadiazole compounds as inhibitors of kynurenine 3-monooxygenase
EP2054397B1 (fr) 2006-08-16 2015-10-07 The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone Inhibiteurs à petites molécules de kynurénine-3-monooxygénase
WO2008052352A1 (fr) 2006-11-03 2008-05-08 The University Of British Columbia Inhibiteurs quinone substitués d'indoléamine 2,3-dioxygénase (ido), leurs synthèses et leurs utilisations
WO2008058178A1 (fr) 2006-11-08 2008-05-15 Incyte Corporation N-hydroxyamidinohétérocycles utilisés comme modulateurs de l'indoleamine 2,3-dioxygénase
DK2141997T3 (da) 2007-03-30 2013-02-11 Sloan Kettering Inst Cancer Konstitutiv ekspression af co-stimulatoriske ligander på adoptivt overførte t-lymfocytter
CA2932121A1 (fr) 2007-11-30 2009-06-11 Newlink Genetics Corporation Inhibiteurs de l'ido
ATE528077T1 (de) 2007-12-07 2011-10-15 Miltenyi Biotec Gmbh Zentrifuge zur trennung einer probe in mindestens zwei komponenten
US8479118B2 (en) 2007-12-10 2013-07-02 Microsoft Corporation Switching search providers within a browser search box
WO2010008427A1 (fr) * 2008-04-11 2010-01-21 Ludwig Institute For Cancer Research Ltd. Catabolisme du tryptophane dans le traitement et le diagnostic du cancer
US20120164718A1 (en) 2008-05-06 2012-06-28 Innovative Micro Technology Removable/disposable apparatus for MEMS particle sorting device
JP5173594B2 (ja) 2008-05-27 2013-04-03 キヤノン株式会社 管理装置、画像形成装置及びそれらの処理方法
EA029781B1 (ru) 2008-07-08 2018-05-31 Инсайт Корпорейшн 1,2,5-оксадиазолы в качестве ингибиторов индоламин-2,3-диоксигеназы
US8691824B2 (en) 2008-08-04 2014-04-08 Chdi Foundation, Inc. Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
CN102238950B (zh) 2008-08-04 2014-05-07 Chdi基金会股份有限公司 某些犬尿氨酸-3-单加氧酶抑制剂、药物组合物以及使用方法
DK3006459T3 (da) 2008-08-26 2021-12-06 Hope City Fremgangsmåde og sammensætninger til forbedring af t-cellers antitumoreffektorfunktion
US8889394B2 (en) 2009-09-07 2014-11-18 Empire Technology Development Llc Multiple domain proteins
CA2776143A1 (fr) 2009-10-01 2011-04-07 The United States Of America, As Represented By The Secretary, Departmen T Of Health And Human Services Recepteurs d'antigenes chimeriques anti-recepteur 2 du facteur de croissance de l'endothelium vasculaire, et leur utilisation pour le traitement du cancer
WO2011044186A1 (fr) 2009-10-06 2011-04-14 The Board Of Trustees Of The University Of Illinois Récepteurs de lymphocytes t à chaîne unique humains
GB0917927D0 (en) 2009-10-13 2009-11-25 Ludwig Inst For Cancer Res Ltd Ido inhibitors and therapeutic uses thereof
WO2011056652A1 (fr) 2009-10-28 2011-05-12 Newlink Genetics Dérivés imidazole comme inhibiteurs de l'ido
AU2010315243B2 (en) 2009-11-03 2016-08-25 City Of Hope Truncated epidermal growth factor receptor (EGFRt) for transduced T cell selection
NZ601547A (en) 2010-01-25 2014-04-30 Chdi Foundation Inc Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
EP2571512B1 (fr) 2010-05-17 2017-08-23 Sangamo BioSciences, Inc. Nouvelles protéines se liant à l'adn et leurs utilisations
PT3012268T (pt) 2010-09-08 2018-01-31 Chemotherapeutisches Forschungsinstitut Georg Speyer Haus Recetores de antigénio quimérico com uma região de charneira otimizada
ES2700966T3 (es) 2010-12-09 2019-02-20 Univ Pennsylvania Utilización de linfocitos T modificados con receptores de antígeno quiméricos para tratar el cáncer
CN103502438A (zh) 2011-03-23 2014-01-08 弗雷德哈钦森癌症研究中心 用于细胞免疫治疗的方法和组合物
NO2694640T3 (fr) 2011-04-15 2018-03-17
US8398282B2 (en) 2011-05-12 2013-03-19 Delphi Technologies, Inc. Vehicle front lighting assembly and systems having a variable tint electrowetting element
EA201490163A1 (ru) 2011-07-28 2014-06-30 Схди Фаундейшн, Инк. Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения
US20130078250A1 (en) 2011-08-23 2013-03-28 Oliver Ast Bispecific t cell activating antigen binding molecules
CN103827095A (zh) 2011-08-30 2014-05-28 Chdi基金会股份有限公司 犬尿氨酸-3-单加氧酶抑制剂、其药物组合物及其使用方法
ES2765805T3 (es) 2011-08-30 2020-06-11 Chdi Foundation Inc Inhibidores de kinurenina-3-monoxigenasa, composiciones farmacéuticas y métodos de uso de los mismos
AU2012325915A1 (en) 2011-10-20 2014-04-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-CD22 chimeric antigen receptors
ES2687954T3 (es) 2011-11-11 2018-10-30 Fred Hutchinson Cancer Research Center Inmunoterapia de linfocitos T dirigidos a ciclina A1 contra el cáncer
CN102579452B (zh) 2012-01-20 2014-05-14 辽宁思百得医药科技有限公司 色胺酮类化合物在制备ido抑制剂中的用途
AU2013221672B2 (en) 2012-02-13 2017-11-09 Seattle Children's Hospital D/B/A Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
WO2013126726A1 (fr) 2012-02-22 2013-08-29 The Trustees Of The University Of Pennsylvania Lymphocytes t doubles transgéniques comportant un car et un tcr, et leurs procédés d'utilisation
WO2013151707A1 (fr) 2012-04-05 2013-10-10 Chdi Foundation, Inc. Inhibiteurs de kynurénine-3-monooxygénase, compositions pharmaceutiques, et procédés d'utilisation de ceux-ci
MX361760B (es) 2012-05-03 2018-12-17 Hutchinson Fred Cancer Res Receptores de celulas t con afinidad aumentada y metodos para hacer los mismos.
GB201211120D0 (en) 2012-06-22 2012-08-01 Bessede Alban Antagonist to an enzyme and/or a metabolite of the kynurenine pathway
DK3494997T3 (da) 2012-07-25 2019-12-02 Broad Inst Inc Inducerbare dna-bindende proteiner og værktøjer til genomperturbation samt anvendelser deraf
SI2884999T1 (sl) 2012-08-20 2021-05-31 Fred Hutchinson Cancer Research Center Metoda in sestavki za celično imunoterapijo
NZ746914A (en) 2012-10-02 2020-03-27 Memorial Sloan Kettering Cancer Center Compositions and methods for immunotherapy
ES2824024T3 (es) 2012-10-10 2021-05-11 Sangamo Therapeutics Inc Compuestos modificadores de células T y usos de los mismos
US9405601B2 (en) 2012-12-20 2016-08-02 Mitsubishi Electric Corporation In-vehicle apparatus and program
CN103070868B (zh) 2013-01-08 2015-08-19 复旦大学 一种含nh-1,2,3-三氮唑的ido抑制剂及其制备方法
MX2015012028A (es) 2013-03-14 2016-02-11 Curadev Pharma Private Ltd Inhibidores de la ruta de quinurenina.
EP2976332B1 (fr) 2013-03-14 2018-01-31 Newlink Genetics Corporation Composés tricycliques utilisés en tant qu'inhibiteurs de l'immunosuppression dont la médiation est assurée par la métabolisation du tryptophane
SG11201506920QA (en) 2013-03-15 2015-09-29 Bristol Myers Squibb Co Ido inhibitors
HUE039339T2 (hu) 2013-03-15 2018-12-28 Bristol Myers Squibb Co Indolamin-2,3-dioxigenáz (IDO) inhibitorai
TWI654206B (zh) 2013-03-16 2019-03-21 諾華公司 使用人類化抗－ｃｄ１９嵌合抗原受體治療癌症
JP6463577B2 (ja) 2013-05-14 2019-02-06 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 改変キメラ抗原受容体（ｃａｒ）ｔ細胞のヒト応用
GB201309421D0 (en) 2013-05-24 2013-07-10 Imp Innovations Ltd Polypeptides
CA2916615A1 (fr) 2013-07-01 2015-01-08 Bristol-Myers Squibb Company Inhibiteurs de l'ido
EP3019488B1 (fr) 2013-07-11 2018-11-07 Bristol-Myers Squibb Company Inhibiteurs de l'ido
US9108442B2 (en) 2013-08-20 2015-08-18 Ricoh Company, Ltd. Image forming apparatus
CN105722522B (zh) 2013-08-30 2021-10-19 得克萨斯大学体系董事会 用于肿瘤疗法的犬尿氨酸耗竭酶的施用
JP6449893B2 (ja) 2013-09-26 2019-01-09 シーエイチディーアイ ファウンデーション，インコーポレーテッド キヌレニン−３−モノオキシゲナーゼ阻害薬、医薬組成物、及びこれらの使用方法
WO2015082499A2 (fr) 2013-12-03 2015-06-11 Iomet Pharma Ltd Composé pharmaceutique
KR20160108568A (ko) 2014-02-04 2016-09-19 인사이트 코포레이션 암을 치료하기 위한 pd-1 길항제 및 ido1 억제제의 조합
WO2015142675A2 (fr) 2014-03-15 2015-09-24 Novartis Ag Traitement du cancer au moyen d'un récepteur antigénique chimérique
MY192522A (en) 2014-04-10 2022-08-25 Seattle Childrens Hospital Dba Seattle Childrens Res Inst Defined composition gene modified t-cell products
CA2945238C (fr) 2014-04-11 2020-09-29 Cellectis Procede permettant la production de cellules immunitaires resistantes a un microenvironnement appauvri en arginine et/ou en tryptophane
IL292512B2 (en) 2014-04-18 2024-07-01 Editas Medicine Inc CRISPR-CAS-related methods, compositions and components for cancer immunotherapy
DK3166968T3 (da) 2014-05-02 2021-12-06 Univ Pennsylvania Sammensætninger og fremgangsmåder til kimæriske autoantistofreceptor-T-celler
GB201413162D0 (en) 2014-07-24 2014-09-10 Immusmol Sas Prediction of cancer treatment based on determination of enzymes or metabolites of the kynurenine pathway
ES2925471T3 (es) 2014-08-13 2022-10-18 Auckland Uniservices Ltd Inhibidores de las triptófano dioxigenasas (IDO1 y TDO) y sus usos en la terapia
GB201414730D0 (en) * 2014-08-19 2014-10-01 Tpp Global Dev Ltd Pharmaceutical compound
WO2016033488A1 (fr) 2014-08-29 2016-03-03 Board Of Regents, The University Of Texas System Administration d'enzymes de déplétion de la kynurénine pour le traitement d'une tumeur
GB201417369D0 (en) 2014-10-01 2014-11-12 Redx Pharma Ltd Compounds
WO2016061231A1 (fr) 2014-10-14 2016-04-21 Deciphera Pharmaceuticals, Llc Inhibition d'interactions de cellules tumorales avec le micro-environnement permettant une réduction de croissance de tumeur et de progression de maladie
WO2016073381A1 (fr) 2014-11-03 2016-05-12 Cerus Corporation Compositions et procédés pour thérapies par cellules car-t améliorées
WO2016145578A1 (fr) * 2015-03-13 2016-09-22 Syz Cell Therapy Co. Procédés de traitement du cancer au moyen de lymphocytes t activés
EP3325504A1 (fr) 2015-07-21 2018-05-30 Novartis AG Méthodes pour améliorer l'efficacité et l'expansion de cellules immunitaires
EP3368559A4 (fr) 2015-10-30 2020-01-15 Aleta Biotherapeutics Inc. Compositions et méthodes pour le du traitement du cancer
WO2017079703A1 (fr) 2015-11-05 2017-05-11 Juno Therapeutics, Inc. Vecteurs et cellules immunitaires génétiquement modifiées exprimant des modulateurs de voie métabolique et utilisations en thérapie cellulaire adoptive
MX2018007421A (es) * 2015-12-17 2018-08-15 Gilead Sciences Inc Compuestos inhibidores de quinasa de union a tank.
CN105567690B (zh) 2016-02-02 2018-08-10 华中科技大学同济医学院附属同济医院 一种抑制ido1表达的抑制剂及其应用
EP3426638B1 (fr) 2016-03-09 2020-05-06 Netherlands Translational Research Center B.V. Inhibiteurs de l'indoléamine 2,3-dioxygénase
US20210177896A1 (en) 2016-06-02 2021-06-17 Novartis Ag Therapeutic regimens for chimeric antigen receptor (car)- expressing cells
KR20190034588A (ko) 2016-07-28 2019-04-02 노파르티스 아게 키메라 항원 수용체 및 pd-1 억제제의 조합 요법
BR112019011025A2 (pt) 2016-12-03 2019-10-08 Juno Therapeutics Inc métodos para modulação de células t car

Also Published As

Publication number Publication date
WO2018071873A9 (fr) 2018-12-20
US20200054673A1 (en) 2020-02-20
AU2017343780B2 (en) 2023-08-31
RU2019113778A3 (fr) 2021-07-15
ES2939646T3 (es) 2023-04-25
EP4190335A1 (fr) 2023-06-07
KR20190084053A (ko) 2019-07-15
WO2018071873A3 (fr) 2018-10-04
PH12019500803A1 (en) 2019-07-15
CN110381963A (zh) 2019-10-25
SG11201903282TA (en) 2019-05-30
MA50839A (fr) 2019-08-21
US11896615B2 (en) 2024-02-13
BR112019006652A2 (pt) 2019-07-02
RU2019113778A (ru) 2020-11-13
CA3037387A1 (fr) 2018-04-19
EP3525803A2 (fr) 2019-08-21
EP3525803B1 (fr) 2022-12-07
AU2017343780A1 (en) 2019-04-04
JP2019533676A (ja) 2019-11-21
JP2022166232A (ja) 2022-11-01
IL265848A (en) 2019-06-30
MX2019004181A (es) 2019-10-30
WO2018071873A2 (fr) 2018-04-19

Similar Documents

Publication Publication Date Title
MA50839A (fr) Méthodes et compositions d'immunothérapie impliquant des modulateurs de la voie métabolique du tryptophane
MA49403A (fr) Compositions de pde5 et méthodes d'immunothérapie
MA46481A (fr) Compositions d'oligonucléotides et méthodes associées
MA50269A (fr) Compositions d'acides nucléiques-polypeptides et méthodes d'induction de saut d'exon
MA44990A (fr) Polythérapies d'inhibiteurs de hdac et d'inhibiteurs de pd-l1
MA43823A (fr) Inhibiteurs bicycliques pontés de ménine-mll et méthodes d'utilisation
MA45996A (fr) Variants d'endonucléase de homing du récepteur alpha de l'il-10, compositions et méthodes d'utilisation associées
MA40938A (fr) Anticorps anti-cd79b et méthodes d'utilisation desdits anticorps
MA42243A (fr) Anticorps de facteur xi et méthodes d'utilisation
DK3452448T3 (da) Modulatorer af den integrerede stressvej
MA43515A (fr) Méthodes et compositions d'inhibition de l'interaction de la ménine avec les protéines mll
MA49715A (fr) Oligomères et conjugués d'oligomères
IL280709A (en) Converted indoles and methods of using them
MA41028A (fr) Méthodes et formulations pour le traitement de pathologies oculaires vasculaires
FR3020060B1 (fr) Preparation d'imides contenant un groupement fluorosulfonyle
GB201617193D0 (en) Amyloid targeting agents and methods of using the same
MA44087A (fr) Immunothérapie basée sur la listéria et ses méthodes d'utilisation
MA43378A (fr) Compositions et méthodes pour la reduction de la réponse immunitaire contre récepteurs d'antigène chimériques
MA43282A (fr) Nouveaux anticorps anti-emr2 et méthodes d'utilisation associées
DK3386523T3 (da) Bifidobacterium longum til behandling af fedme og associerede metabolske sygdomme
UY34115A (es) Ensayo de la lisil oxidasa-like 2 y sus métodos de empleo
MA44862A (fr) Formulations de fulvestrant et méthodes d'utilisation de celles-ci
MA41642A (fr) Variants de protoxine ii et méthodes d'utilisation
MA51056A (fr) Compositions et méthodes pour le traitement d'affections métaboliques
MA45987A (fr) Agonistes des récepteurs 5-ht2c, compositions et méthodes d'utilisation